

Drugs and Devices Division

Drug Submission Status

Report for November 2019

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Fingolimod	Gilenya	fingolimod	0.5mg	capsule	02469936
Taro Pharmaceuticals Inc.	Taro-Fingolimod	Gilenya	fingolimod	0.5mg	capsule	02469618
Marcan Pharmaceuticals Inc.	Mar-Fingolimod	Gilenya	fingolimod	0.5mg	capsule	02474743
Sandoz Canada Inc.	Sandoz Fingolimod	Gilenya	fingolimod HCl	0.5mg	capsule	02482606
Teva Canada Limited	Teva-Febuxostat	Uloric	febuxostat hemihydrate	80mg	tablet	02466198
Apotex Inc.	Apo-Gatifloxacin	Zymar	gatifloxacin hemihydrate	0.3%w/v - 5mL bottle	ophthalmic solution with preservative	02327260